HTD Stock Overview
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Corcept Therapeutics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.41 |
| 52 Week High | US$31.60 |
| 52 Week Low | US$19.40 |
| Beta | 0.48 |
| 1 Month Change | 0.43% |
| 3 Month Change | 10.42% |
| 1 Year Change | 7.39% |
| 3 Year Change | 39.35% |
| 5 Year Change | 144.03% |
| Change since IPO | 133.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| HTD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.5% | 3.8% | 1.9% |
| 1Y | 7.4% | -25.3% | 4.6% |
Return vs Industry: HTD exceeded the German Pharmaceuticals industry which returned -25.3% over the past year.
Return vs Market: HTD exceeded the German Market which returned 4.6% over the past year.
Price Volatility
| HTD volatility | |
|---|---|
| HTD Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HTD has not had significant price volatility in the past 3 months.
Volatility Over Time: HTD's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 352 | Joseph Belanoff | www.corcept.com |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
Corcept Therapeutics Incorporated Fundamentals Summary
| HTD fundamental statistics | |
|---|---|
| Market cap | €2.46b |
| Earnings (TTM) | €109.07m |
| Revenue (TTM) | €487.20m |
22.6x
P/E Ratio5.1x
P/S RatioIs HTD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTD income statement (TTM) | |
|---|---|
| Revenue | US$523.53m |
| Cost of Revenue | US$7.63m |
| Gross Profit | US$515.90m |
| Other Expenses | US$398.70m |
| Earnings | US$117.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.13 |
| Gross Margin | 98.54% |
| Net Profit Margin | 22.39% |
| Debt/Equity Ratio | 0% |
How did HTD perform over the long term?
See historical performance and comparison